2 Comments

CHAPTER 110 MEGAKARYOPOIESIS AND THROMBOPOIESIS

CHAPTER 110 MEGAKARYOPOIESIS AND THROMBOPOIESIS
Williams Hematology

CHAPTER 110 MEGAKARYOPOIESIS AND THROMBOPOIESIS

DAVID J. KUTER

Anatomy of Megakaryocytes

Polyploidy

Megakaryocyte Granules

Megakaryocyte Surface Membrane

Light Microscopic Appearance of Megakaryocytes
The Origin of Megakaryocytes

Early Megakaryocyte Progenitors

Late Megakaryocyte Progenitors

Effects of Thrombopoietic Growth Factors
Platelet Production and Release

The Formation of Platelets from Megakaryocytes

Regulation of Platelet Size
The Molecular Biology of Megakaryocyte Differentiation

GATA-1

NF-E2
The Regulation of Megakaryocytopoiesis and Thrombopoiesis

Physiological Principles

Thrombopoietin

The Role of Thrombopoietin in Normal Physiology
Megakaryocytes in Disease

Megakaryocyte Hypoplasia Secondary to Chemotherapy

Pernicious Anemia

Congestive Splenomegaly

Thrombocytopenia Associated with Human Immunodeficiency Virus (HIV)

Idiopathic Thrombocytopenic Purpura

Reactive Thrombocytosis

Essential Thrombocythemia

Myelodysplastic Syndromes

Hematopoietic Disorders Associated with Abnormal Chromosome 3Q

Agnogenic Myelofibrosis with Myeloid Metaplasia

Disorders of Thrombopoietin Production
Recombinant Thrombopoietic Growth Factors and their Clinical Uses

Thrombopoietin

Interleukin-11

Other Thrombopoietic Growth Factors
Chapter References

Large, polyploid, bone marrow megakaryocytes shed enucleate platelets into the circulation. Most of the proteins and granules that determine the characteristics of these platelets are made in the megakaryocytes. In response to an increased need for platelets, megakaryocytes increase their number, size, and ploidy; the opposite effects occur when the demand decreases. The growth of megakaryocytes and the production of platelets are regulated almost entirely by the amount of thrombopoietin in the circulation. Upon binding to the thrombopoietin receptor, c-Mpl, thrombopoietin increases the growth of early marrow precursors of all lineages but only stimulates the maturation of late precursors of the megakaryocyte lineage and thereby increases only platelet production. Thrombopoietin is produced at a constant rate in the liver, and its level is determined primarily by the rate of clearance by c-Mpl receptors on platelets and possibly megakaryocytes. Characteristic changes in megakaryocytes occur in a wide variety of disorders of abnormal platelet production. Recombinant thrombopoietins as well as other hematopoietic growth factors such as interleukin-11 can increase platelet production and may become clinically useful.

Acronyms and abbreviations that appear in this chapter include: 5–FU, 5–fluorouracil; CHO, Chinese hamster ovary; GEMM-CFC, or mix-CFC, granulocyte-erythroid-macrophage-megakaryocyte colony-forming cells; HIV, human immunodeficiency virus; ITP, idiopathic thrombocytopenic purpura; MGDF, megakaryocyte growth and development factor; meg-BFC, megakaryocytic burst-forming cell; meg-CFC, megakaryocyte colony-forming cell; MPV, mean platelet volume; PEG-rHuMGDF, pegylated, recombinant megakaryocyte growth and development factor; PF4, platelet factor 4; rHuTPO, recombinant human thrombopoietin; vWf, von Willebrand factor.

The derivation of blood platelets from megakaryocytes has been known since 1906,1 but the process of platelet production (termed thrombopoiesis or thrombocytopoiesis) remains enigmatic. Megakaryocytes are very large, polyploid bone marrow cells whose low prevalence has made their investigation difficult. During the past two decades, in vitro cloning of megakaryocytic progenitors, production of monoclonal antibodies that specifically identify megakaryocytes and their constituents, and new molecular techniques have advanced our knowledge of megakaryocyte biology (called megakaryopoiesis or megakaryocytopoiesis). With the purification of thrombopoietin2,3,4,5,6 and 7 great strides have been made in understanding the physiology of platelet production from megakaryocytes.
ANATOMY OF MEGAKARYOCYTES
In lower vertebrate species such as fish and birds, all the circulating blood cells, including the erythrocytes and the platelets (called thrombocytes), are nucleated and are produced by diploid bone marrow precursor cells.8 However, in higher vertebrates platelets are produced by a different mechanism whose evolutionary advantage is unclear. Anucleate platelets9 are generated from unusual bone marrow cells, the megakaryocytes. Megakaryocytes normally account for approximately 0.05 to 0.1 percent of all nucleated human bone marrow cells, but their number increases as the demand for platelets rises. In contrast to the erythrocyte with a diameter of 5µm and a volume of 85 to 100 fl, megakaryocytes have average diameters of 20 to 25 µm and volumes of 4700 ± 100 fl.10 Some of the largest megakaryocytes may have diameters of 50 to 60 µm and volumes of 65,000 to 100,000 fl. These unique cells are polyploid and contain platelet-specific granules and proteins.
POLYPLOIDY
Mature megakaryocytes are invariably polyploid and contain from two (4N) to 32 (64N) times the normal diploid amount of DNA.11,12 Human megakaryocytes have a mean ploidy of 16N. Unlike the small percentage of hepatocytes and macrophages that have two- to four-fold the normal diploid content of DNA and whose DNA is contained in multiple separate nuclei, all of the DNA in megakaryocytes is contained within one highly lobulated nuclear envelope where each nuclear lobule represents one diploid amount (2N) of DNA. In general there is a relationship between increased ploidy and increased megakaryocyte size, but given the time needed for the cytoplasm of megakaryocytes to mature, not all small megakaryocytes are of low ploidy. In fetal life megakaryocytes are less polyploid; cultured mature megakaryocytes from fetal liver at 8 to 10 weeks of gestation are only 2N and 4N, while 8N megakaryocytes are detected at 20 weeks of gestation.13
At some ill-defined point in the megakaryocytic differentiation pathway, mitosis ceases and the unusual process of endomitosis (also called polyploidization or endoreduplication) commences.14 Endomitosis is a process in which DNA replication occurs but neither the nucleus nor the cell undergoes division (cytokinesis). Morphologically, endomitosis is associated with the dissolution of the nuclear membrane and the formation of a multipolar mitotic spindle.15 While initially it was assumed that endomitosis was simply the absence of mitosis after each round of DNA replication, studies in mice16 showed that megakaryocytes indeed enter mitosis and progress through normal prophase, prometaphase, metaphase, and up to anaphase A, but not to anaphase B, telophase, or cytokinesis. After anaphase, the nuclear membrane is reassembled about the sister chromatids as a single nucleus skipping telophase and cytokinesis, and the cells enter the next round of DNA replication.
Cessation of mitosis in the diploid megakaryocyte progenitors is apparently directly coupled to the start of endoreduplication, and it is generally assumed that most cells greater than 4N in ploidy are committed to endomitosis and rarely divide mitotically. The probability of entering the endomitotic pathway is hierarchically dependent upon the state of differentiation of the progenitor.17 Thus, the more primitive the progenitor is, the more likely it is to remain a mitotic cell. Genes with known roles in regulating the cell cycle such as the cyclin-dependent kinases and the cyclins have been studied. Although results are incomplete, during endomitosis cyclin D3 is increased,18 and the levels of cyclin B1 and cyclin B1-dependent Cdc2 kinase are reduced.19 These events may allow the megakaryocyte to abort some aspects of mitosis and reenter a phase of DNA replication without cytokinesis.20
MEGAKARYOCYTE GRANULES
Since platelets can produce only very small amounts of protein, their cytoplasmic characteristics are mostly determined by the megakaryocytes from which they come. Four distinct categories of granules differing in their internal constituents are produced by maturing megakaryocytes: alpha (a), dense, lysosomal, and microperoxisomal (Fig. 110-1a–e).

FIGURE 110-1 (a) Ultrastructure of the cytoplasm of a mature megakaryocyte. The majority of the granules are a granules (a-Gr) exhibiting dense nucleoid. Demarcation membranes (DM) are slightly dilated. Transverse sections of microtubules (Mt) are dispersed; at the periphery, a longitudinal microtubule runs under the cell membrane (arrows). Dense aggregates of glycogen (Gly), small cisternae of endoplasmic reticulum (ER), and free ribosomes can be recognized. ×30,320. (b) Morphology of an a granule. Dense nucleoid is located at the top; in a clear zone at the opposite pole, four transverse sections of tubular structures are seen adjacent to the granule membrane. ×37,200. (c) A dense body can be distinguished from an a granule by the black deposit when calcium is added to the fixative. ×37,200. (d) Cytochemical detection of acid phosphatase using b-glycophosphate as substrate and cerium as a trapping agent. Dense cerium-phosphate precipitates are present in lysosomal granules while a granules are unreactive. ×37,200. (e) Microperoxisome visualized using alkaline diaminobenzidine. Note the small size of a reactive granule compared to an a granule. ×37,200. (f) Distribution of a dense tracer filling the lumen of the demarcation membrane system in a maturing megakaryocyte. This system appears to outline some platelet territories (arrows). In contrast to the demarcation membrane system, which is open to the extracellular space, the endoplasmic reticulum (ER) is not labeled. ×9700. (Courtesy of Dr. Janine Breton-Gorius.)

a GRANULES
The a granules (which are azurophilic on stained smears) are the most numerous granules seen with the electron microscope.21 The granule body itself is made early in megakaryocyte development before the demarcation membrane system and first appears in the Golgi apparatus of megakaryoblasts (stage I megakaryocytes).22 Several platelet proteins, including von Willebrand factor (vWf), platelet factor 4 (PF4), and thrombospondin have been detected in early megakaryocyte progenitors prior to the appearance of a granules.23 Figure 110-1b shows that a granules exhibit distinct zones: a diffuse granular matrix, a dense nucleoid, and a third electron-lucent compartment containing from one to six tubular structures close to the membrane.24 Immunoelectron microscopy has shown that several of the a granule proteins are compartmentalized; for example, vWf is associated with tubular structures similar to those of the vWf storage organelles of the vascular endothelium (Weibel-Palade bodies). Thrombospondin and fibrinogen are localized in the matrix,25,26 and 27 and b-thromboglobulin (b-TG) and PF4, together with mucopolysaccharides, are present in the dense nucleoid.28,29 and 30
Although some of the a granule proteins such as platelet-derived growth factor, transforming growth factor-b, PF4, and vWf are synthesized in the megakaryocyte and transported to the a granules,31 other proteins such as fibrinogen undergo GPIIb/IIIa receptor-mediated endocytosis from the plasma into the a granules of both megakaryocytes and platelets.32,33,34 and 35 Still others, such as albumin and IgG are pinocytosed from the plasma into the a granules of megakaryocytes and platelets.36 The location of megakaryocytes in close proximity to vascular sinuses may facilitate uptake of these circulating proteins.37
Several proteins have been detected on the membrane of a granules: GPIIb/IIIa,38 P-selectin (CD62P; GMP-140 or PADGEM),39 GMP-33,40 and platelet osteonectin.41
DENSE GRANULES
Dense granules constitute a class of granules distinguishable from a granules by their morphology (Fig. 110-1c) and their content: a nonmetabolic pool of adenine nucleotides synthesized by megakaryocytes, and calcium and serotonin.42 Dense granules of platelets are physically dense, and because of their content of serotonin and calcium, they are also electron-dense when viewed with the transmission electron microscope. The dense granule membrane bodies are made in megakaryocytes but do not acquire their content of serotonin and calcium until platelets are released into the circulation and then uptake calcium and most of the body’s circulating serotonin.43,44 This ability to accumulate and store serotonin constitutes an early marker of megakaryocytes, since even the earliest megakaryocyte progenitors are able to incorporate exogenous serotonin.44,45 The membrane of dense bodies expresses granulophysin46 and P-selectin.47
LYSOSOMAL GRANULES
Lysosomal granules are a unique class of granules as judged by ultrastructural cytochemical localization of arylsulfatase and acid phosphatase (Fig. 110-1d), the immunolocalization of cathepsin D, and the identification of lysosome-associated membrane protein.48,49 and 50 They are formed very early during maturation, prior to the appearance of a granules.
MICROPEROXISOME GRANULES
Small granules (90 nm) that arise prior to a granule formation have been shown to contain catalase.51 These granules appear similar to the microperoxisomes of other cells (Fig. 110-1e).
MEGAKARYOCYTE SURFACE MEMBRANE
DEMARCATION MEMBRANE SYSTEM
The surface membrane of the mature megakaryocyte is deeply invaginated and highly redundant (Fig. 110-1a). It divides the cytoplasm into platelet-sized “territories” and has thus been termed the demarcation membrane system.52,53 Since the lumen of the demarcation membrane system stains with extracellular tracers (Fig. 110-1f), it is continuous with the extracellular medium.52,54 The total area of the surface and demarcation membranes may increase by 26-fold during a 72-h maturation period.52 This enormous amplification of the surface membrane is required to form platelets.52,55,56
PLATELET GLYCOPROTEINS
Both the megakaryocyte cell membrane and the demarcation membrane system express GPIIb/IIIa and GPIb/IX complexes; however, these platelet glycoproteins appear first on the plasma membrane prior to the formation of the demarcation membrane system.57 One of the first signs of differentiation along the megakaryocyte lineage is the appearance on the surface of CD34+ progenitors of the platelet GPIIb/IIIa receptor,58 and its expression increases in parallel with the decline of CD34 expression during maturation.59 GPIIb has been considered to be specific for the megakaryocyte-platelet lineage.60 This is later followed by the appearance of the GPIb/IX complex57 and the collagen receptors. Expression of GPIb/IX, a receptor for vWf,61 correlates with the onset of ploidization.59 This complex has been thought to be platelet-specific, although cytokine-activated endothelial cells may also express a form of GPIb.62,63 and 64
LIGHT MICROSCOPIC APPEARANCE OF MEGAKARYOCYTES
The large, mature, polyploid megakaryocytes are readily identified by light microscopy (see Plate XXX) and are often located adjacent to bone marrow sinusoids.37 Occasionally they may actually be seen to be shedding platelets.1,65 In addition to the mature megakaryocytes, several other earlier maturational stages of megakaryocytes may be identified66 using a classification scheme based on the nuclear/cytoplasmic ratio, nuclear shape, basophilia, and granularity (Table 110-1).67 These early megakaryocytes are often distant from the sinusoid.

TABLE 110-1 MATURATION STAGES OF MEGAKARYOCYTES

Also present in the bone marrow are small, diploid megakaryocyte progenitor cells called promegakaryoblasts that are transitional cells committed to the process of endomitosis but not yet polyploid.68,69,70,71 and 72 In humans these cells have the size and morphology of lymphocytes and express GPIIb on their membrane and vWf or PF4 in their cytoplasm.23,73,74 This population is equivalent to the small acetylcholinesterase-positive marrow cells in rodents.69 (In rodents and cats, acetylcholinesterase is a specific marker for platelets and megakaryocytes69; in humans acetylcholinesterase appears to be present in immature, but not mature megakaryocytes.75) Some of these cells may retain proliferative capacity,72 but the majority of these transitional cells do not form colonies in culture. They are, however, capable of maturing into typical polyploid megakaryocytes71,76 and constitute 4 percent of all megakaryocytes.77,78 and 79 Ultrastructurally, human promegakaryoblasts are recognizable by the cytochemical demonstration of platelet peroxidase, which is present exclusively in the endoplasmic reticulum (Fig. 110-2).54 This enzyme, which is present throughout megakaryocytic maturation and is detectable in platelets, is involved in prostaglandin synthesis.80 Although several other types of marrow cells capable of transient prostaglandin synthesis exhibit a similar peroxidase activity, nonmegakaryocytes possess characteristics that distinguish them from promegakaryoblasts.81,82 Simultaneous analysis of membrane GPIIb and platelet peroxidase has shown that the latter constitutes the first marker of megakaryocyte maturation.83

FIGURE 110-2 (a) Electron micrograph of a normal human marrow promegakaryocyte treated for the detection of platelet peroxidase. This small cell (<9 µm) exhibits a dense reaction product, demonstrating the presence of platelet peroxidase in the perinuclear space and in the endoplasmic reticulum (arrows). ×12,150. (Inset) Enlargement of the Golgi zone. The Golgi saccules and vesicles are devoid of platelet peroxidase (open arrows), while the endoplasmic reticulum contains platelet peroxidase activity (closed arrow). ×25,000. (b) Maturing megakaryocyte in the marrow. The large megakaryocyte is located close to the sinus endothelium, and a small cytoplasmic bleb (arrow) is in direct contact with the blood. A neutrophil (N) is seen in the sinus. ×3600. (Courtesy of Dr. Janine Breton-Gorius.)

THE ORIGIN OF MEGAKARYOCYTES
Like all other bone marrow cells, megakaryocytes are derived from the pluripotential stem cell (Fig. 110-3). The cellular steps by which the stem cell becomes a megakaryocyte have been defined by in vitro colony studies and include early progenitors having the capacity to produce colonies consisting of cells of several lineages [such as granulocyte-erythroid-macrophage-megakaryocyte colony-forming cells (GEMM-CFC) or Mix-CFC] and later progenitors committed only to megakaryocyte differentiation.84,85

FIGURE 110-3 The origin and development of megakaryocytes. The pluripotential stem cell produces a progenitor cell committed to megakaryocyte differentiation (meg-CFC) which can undergo mitosis. Eventually the meg-CFC stops mitosis and enters endomitosis during which neither cytoplasm nor nucleus divides but DNA replication proceeds and gives rise to polyploid immature precursor cells. Upon completion of endomitosis, the immature progenitor cells become large, morphologically identifiable, mature megakaryocytes that shed platelets.

EARLY MEGAKARYOCYTE PROGENITORS
Although most CD34+/CD38– cells express the thrombopoietin receptor, c-Mpl, on their surface,86 few express other megakaryocyte-specific antigens. These cells ultimately give rise to multipotential progenitors such as the GEMM-CFC and probably also to progenitors committed to erythrocyte, megakaryocyte, and mast cell differentiation. There is no specific assay for this latter common progenitor cell, but there is a close relationship between early erythroid and megakaryocyte differentiation at the molecular, cellular, and pathological levels. For example, common transcription factors exist in these two lineages,87 and their regulatory hematopoietic cytokines, erythropoietin and thrombopoietin, are 50 percent similar.3 Both share the common cis-acting sequence, GATA-1,88,89 which is present in the promoter regions of many genes. In addition, in mice in which the thymidine kinase gene was expressed under the control of the GPIIb promoter, administration of gancyclovir resulted in eradication of both megakaryocyte and erythroid progenitors,90 suggesting that the GPIIb promoter was transcriptionally active in a bipotential progenitor cell91 and possibly in a totipotent progenitor cell.92
LATE MEGAKARYOCYTE PROGENITORS
At some point, the differentiation process produces precursor cells committed only to megakaryocyte differentiation. The transition between multipotent progenitors and megakaryocyte-restricted progenitors may involve the c-mpl oncogene, which is highly expressed in megakaryocyte cell lines and progenitor cells.93 Inhibition of c-mpl function in vitro has been reported to decrease megakaryocyte differentiation of primitive progenitors.94 A hierarchical classification system of megakaryocytic progenitors has been devised based on proliferative characteristics in culture, membrane antigen expression, and physical properties.95,96,97 and 98 The more immature progenitors have the greatest capacity for proliferation, a capacity that declines as the progenitor differentiates.99 The earliest definable committed progenitor, the megakaryocytic burst-forming cell (meg-BFC),95 gives rise to clusters of megakaryocytes (100 cells or more), is fully expressed at 21 days following initiation of culture, is resistant to 5-fluorouracil (5-FU) treatment, expresses the hematopoietic stem cell marker CD34, and is HLA-DR-negative.96,99
A later progenitor, the megakaryocyte colony-forming cell (meg-CFC),100,101 gives rise to colonies composed of smaller numbers of megakaryocytes, is expressed at 12 days of culture, is sensitive to 5-FU, expresses membrane GPIIb/IIIa102,103 and HLA-DR antigens,99 and undergoes mitosis.104 The CD34 antigen declines progressively with increasing maturity of the progenitors and is lost in the polyploid immature megakaryocyte.59
Eventually the meg-CFC stops mitosis and enters endomitosis in which polyploid precursors with scant cytoplasm are produced (Fig. 110-3). Upon the completion of endomitosis, immature megakaryocytes develop a mature cytoplasm, become morphologically identifiable, and eventually release platelets. Overall, it takes approximately 5 to 7 days to progress from the meg-CFC to the platelet. Morphologically identifiable megakaryocytes rarely divide.
EFFECTS OF THROMBOPOIETIC GROWTH FACTORS
The primary regulator of platelet production, thrombopoietin, has a major effect on almost all steps of megakaryocyte differentiation and maturation. It promotes the growth of meg-CFC, dramatically increases the rate of endomitosis, and stimulates megakaryocyte maturation.105,106 Increased megakaryocyte ploidy is seen at even very low concentrations of thrombopoietin and is the most sensitive indicator of the effect of thrombopoietin. However, the final stage of platelet release is not dependent on thrombopoietin and actually may be inhibited by large amounts of thrombopoietin.107 Other cytokines such as IL-3,108,109,110 and 111 IL-6,112,113,114,115,116,117,118,119 and 120 and IL-11121,122,123 and 124 can also promote meg-CFC growth and megakaryocyte maturation but lack much effect on endomitosis; they can all increase platelet production in vivo. Transforming growth factor b inhibits megakaryocyte growth and platelet production in vitro and in vivo.125,126 and 127 Interferon alpha and beta inhibit the growth of meg-CFC,128,129,130,131,132 and 133 but interferon gamma stimulates meg-CFC growth.134 Interferon alpha has been used clinically to reduce the platelet count in patients with essential thrombocythemia and other myeloproliferative disorders129,135,136; in patients with chronic hepatitis, interferon alpha produces a rapid decrease in the platelet count.137
PLATELET PRODUCTION AND RELEASE
THE FORMATION OF PLATELETS FROM MEGAKARYOCYTES
Although historically one of the first observations was the apparent shedding of platelets by megakaryocytes,1,65 the exact mechanism by which platelets are produced remains unclear. Incomplete data suggest that platelets are not shed from megakaryocytes with ploidy less than 8N and that larger megakaryocytes make more platelets than smaller ones. Each megakaryocyte produces an average of 1000 to 3000 platelets, and it has been estimated that 35,000 to 45,000 platelets per microliter of blood are produced per day.10,138,139 During times of marked platelet demand, normal production may increase sixfold.10 Three different mechanisms of platelet production from megakaryocytes have been proposed.
PLATELET TERRITORIES MODEL
The megakaryocyte cytoplasm is divided by the demarcation membrane system into future platelet “territories” (Fig. 110-1f), and the megakaryocyte then simply fractures into separate platelets.140 The platelets would be released into the marrow and then somehow pass into the sinusoids, leaving behind the bare megakaryocyte nucleus. Support for this mechanism comes primarily from electron microscopic data showing these platelet territories in megakaryocytes but not the more dynamic process of them fracturing into platelets. However, few bare megakaryocyte nuclei are seen in the bone marrow, and there is no evidence that platelets pass through the endothelial cells lining the sinusoids.
PROPLATELET MODEL
Megakaryocytes use the highly redundant demarcation membrane system to send pseudopodia out into the bone marrow sinusoids,52,55,141,142 and 143 and platelets and proplatelets bud off. Proplatelets are elongated strands of megakaryocyte cytoplasm (Fig. 110-4) that are larger than normal platelets141,144 and later fragment into a number of platelets. The bone marrow sinusoids are lined by very thin endothelial cells that are tightly bound to each other and may even overlap.141 The megakaryocyte pseudopodia actually pass through, not between, the endothelial cells, which may in turn play some role in regulating the process.141 This is the method initially suggested in 1906,1,65 and most subsequent data confirm many elements of this model. For example, the culture of mature megakaryocytes on basement membrane matrix leads to increased proplatelet formation.145,146 and 147 Platelets may then be liberated from these elongated processes by rupture of the links. In mice recovering from severe thrombocytopenia there are increased numbers of proplatelet processes in the sinusoids.90 Also in mice lacking the transcription factor NF-E2, the severe thrombocytopenia that is present is probably related to the inability of the megakaryocytes to form proplatelet processes.148,149 A similar defect occurs in mice with selective loss of the transcription factor GATA-1.150

FIGURE 110-4 Megakaryocyte proplatelet processes in the bone marrow sinusoid. This scanning electron micrograph shows the luminal view of the confluence of two bone marrow sinusoids with two proplatelet processes protruding through the lining endothelial cells. One of the processes has intermittent constrictions (arrows) indicating potential sites for platelet formation. Other cells depicted include lymphocytes and erythrocytes (×3000). Reproduced by permission from reference 141.

PULMONARY PLATELET PRODUCTION MODEL
Megakaryocytes or proplatelets are released from the bone marrow, travel to the lung, and are transformed into platelets therein by shear forces.151,152 and 153 This model is a further elaboration of the proplatelet model in which the locus of the production of single platelets is not in the bone marrow but in the lungs. Evidence for this mechanism is the following: (1) the demonstration that megakaryocytes can cross the bone marrow endothelial cell barrier90,154; (2) the presence of megakaryocytes and megakaryocyte nuclei in the circulation and in the pulmonary vessels151,153; (3) mathematical models suggesting that both the platelet number and the log-normal platelet size distribution can be explained by this method of platelet production.152,155 Whether these pulmonary megakaryocytes are simply occasional errant megakaryocytes that have escaped from the marrow and become trapped in the lungs or reflect a major route of cell trafficking is unclear. It has been estimated that the total amount of pulmonary megakaryocytes may account for most of the platelet production,156 but direct evidence for this is still lacking.
REGULATION OF PLATELET SIZE
Circulating platelets vary greatly in their size, density, and age.157,158 Although platelets have a log-normal distribution of sizes,152,155 the cellular mechanisms accounting for the size of platelets is poorly understood. It is unclear whether large platelets come from large, high-ploidy megakaryocytes or small, low-ploidy megakaryocytes; evidence for either exists.158,159 and 160 In general, the mean platelet volume (MPV) increases as the platelet count decreases160,161 and the larger platelets are assumed to be younger162,163,164,165 and 166 and more reactive.167 This effect is seen clinically in patients with chronic idiopathic thrombocytopenic purpura (ITP) in whom the MPV is increased due to an increased number of large platelets, called megathrombocytes; the presence of megathrombocytes is useful in distinguishing ITP from some of the other thrombocytopenic disorders.163,164,165 and 166 In reactive thrombocytosis the MPV is not increased.
The effect of thrombopoietin on platelet size is variable. In mice, administration of low doses of thrombopoietin decreased the MPV, intermediate doses produced an initial increase followed by a later decrease, and high doses gave an initial increase followed by a normalization of the MPV.168,169 In humans administered a recombinant form of thrombopoietin, the MPV usually decreased in a manner inversely proportional to the platelet count.170
THE MOLECULAR BIOLOGY OF MEGAKARYOCYTE DIFFERENTIATION
The molecular mechanisms by which cells become committed to the megakaryocyte lineage are just starting to be unraveled. Unlike hematopoietic growth factors such as thrombopoietin, which appear to prevent apoptosis and stimulate growth of cells already committed to megakaryocyte differentiation, intrinsic lineage-specific transcription factors become expressed in uncommitted precursor cells and then establish cell-specific phenotypes. The transcription factors GATA-1 and NF-E2 have been shown to be important in megakaryocyte development. The lineage-specific genes that are, in turn, controlled by these factors remain unknown.
GATA-1
This zinc-finger transcription factor is expressed in erythroid cells, megakaryocytes, eosinophils, and mast cells. Elimination of the entire GATA-1 gene results in embryonic death due to severe anemia.171 Since GATA-1 is found in megakaryocytes, and GATA-1 binding sites are found in many genes specific for megakaryocytes and platelets, it was anticipated that GATA-1 played a role in megakaryocyte development. When a unique portion of the GATA-1 promoter was disrupted, GATA-1 expression was eliminated in megakaryocytes but not in erythrocytes. Animals with this disrupted GATA-1 promoter were not anemic, but they had platelet counts 15 percent of normal and an increased number of small, abnormal megakaryocytes with multilobulated nuclei.150 The megakaryocytes had scant cytoplasm, few demarcation membranes, no platelet “territories,” and few platelet granules; they rarely formed proplatelets, suggesting an early defect in cytoplasmic maturation and consequently diminished platelet production. In addition these megakaryocytes had an increased proliferative capacity in vitro.87
NF-E2
This heterodimeric basic leucine zipper transcription factor is composed of a widely expressed p18 subunit and a p45 subunit present only in erythroid cells, megakaryocytes, and mast cells. When NF-E2 was disrupted, mice developed a mild anemia and a profound thrombocytopenia associated with a high rate of early hemorrhagic death.172,173 These mice had adequate numbers of large, abnormal megakaryocytes with hyperlobulated nuclei, rare granules, and adequate amounts of demarcation membranes, but no platelet “territories.” The mice never appear to form proplatelets.149 NF-E2 appears to affect megakaryocyte cytoplasmic differentiation and platelet production at a somewhat later step than GATA-1.174
THE REGULATION OF MEGAKARYOCYTOPOIESIS AND THROMBOPOIESIS
PHYSIOLOGICAL PRINCIPLES
Over the past 50 years a number of principles of the regulation of platelet production have emerged from clinical studies175:

1.
The platelet count in any individual remains constant throughout life unless perturbed by physiological (e.g., pregnancy) or pathological (e.g., myelodysplasia) processes.176

2.
Among normal individuals there is a large variation in platelet counts, ranging from 150–450 × 109/liter.162 This is unlike the erythrocyte count, which is much less variable between individuals.

3.
There is an inverse relationship between the normal platelet count and the normal mean platelet volume (MPV),177 and this produces a roughly constant circulating platelet mass.158,178 This inverse relationship extends to other species; for example, mice have a normal platelet count of 1200 × 109/liter and an MPV of 4.7 fl whereas porcupines have a normal platelet count of 30 × 109/liter and an MPV of 105 fl.179

4.
The body “defends” the total mass of platelets, not the platelet count. Normally approximately one-third of the total platelet mass is sequestered in an exchangeable splenic pool.180 In animals181,182 or humans with enlarged spleens,180 the platelet count decreases proportionally to the increase in the size of the spleen, but the total body mass of platelets remains normal and unchanged.

5.
The bone marrow megakaryocytes respond to changes in the demand for platelets by altering their number, size, and ploidy. In animals12,183,184 made thrombocytopenic by the injection of antibody to platelets, bone marrow megakaryocytes increase their number, size, and ploidy. In animals made thrombocytotic by platelet transfusion, the opposite changes in megakaryocytes occur (Fig. 110-5).

FIGURE 110-5 The physiological response of bone marrow megakaryocytes to changes in the platelet count. Mice were made acutely thrombocytopenic by the injection of antiplatelet antibody (a) or made thrombocytotic by the transfusion of platelets (c) and compared with untreated mice (b). The number, size, and nuclear lobulation of bone marrow megakaryocytes increased during thrombocytopenia and decreased during thrombocytosis when compared with normal animals (×16). Reproduced by permission.184

6.
Meg-CFC do not respond acutely to the stimulus of thrombocytopenia185,186; rather, increased meg-CFC are observed subsequent to the alterations that are noted in the more differentiated megakaryocytes.185 Similarly, thrombocytosis does not result in a compensatory decrease in meg-CFC.185 These in vivo observations imply that the initial response to platelet demand is focused on the more mature nonmitotic megakaryocytes.
THROMBOPOIETIN
For almost 50 years it had been assumed that a thrombopoietin existed that regulated platelet production just as erythropoietin controlled the production of erythrocytes.187 Despite heroic efforts, it was not until 1994 that this protein was finally purified and cloned and called by several different names: thrombopoietin,5,188 c-Mpl ligand,3 megakaryocyte growth and differentiation factor (MGDF),6 or megapoietin.2 Although thrombopoietin is the historically accepted name for this protein, the term c-Mpl ligand is also appropriate given the finding that c-Mpl is the receptor for thrombopoietin. This receptor had been discovered in a murine retrovirus that caused a myeloproliferative leukemia (i.e., “mpl”) prior to the purification of thrombopoietin. The oncogene responsible for that syndrome, v-mpl, was found to encode a novel truncated hematopoietic growth factor receptor.189 When the full-length cellular homologue, c-mpl, was cloned, it was found to be a new hematopoietic growth factor receptor of unknown function that was present primarily on megakaryocytes and platelets93 and if inhibited resulted in a decrease in the growth of meg-CFC.94 This receptor was then used to help purify the c-Mpl ligand. It was subsequently demonstrated that the c-Mpl ligand was indeed thrombopoietin and that the c-Mpl receptor was the thrombopoietin receptor.190,191,192 and 193
STRUCTURE OF THROMBOPOIETIN
Thrombopoietin is produced primarily in liver parenchymal cells, while much smaller amounts are made in the kidney.194 Thrombopoietin is synthesized as a 353–amino acid precursor protein with a molecular mass of 36 kDa.3,6,195 Following the removal of the 21–amino acid signal peptide, the remaining 332 amino acids undergo glycosylation to produce an 80- to 90-kDa glycoprotein. The glycoprotein is then released into the circulation with no apparent intracellular storage in the liver or kidney.
Thrombopoietin is an unusual hematopoietic growth factor in a number of ways. First it is much larger than most other regulators of blood cell production such as G-CSF and erythropoietin. Second it has an unusual structure with an erythropoietin-like domain and a carbohydrate-rich domain. The first 153 amino acids of the mature protein are 23 percent homologous with human erythropoietin196 and probably 50 percent similar if conservative amino acid substitutions are considered. This region also contains four cysteine residues just like those in erythropoietin and is highly conserved among different species. Despite these similarities with erythropoietin, thrombopoietin does not bind to the erythropoietin receptor and erythropoietin does not bind to the thrombopoietin receptor.
Amino acids 154 to 332 comprise a novel sequence that contains six N-linked glycosylation sites; this region is less well conserved among different species. Structure-function studies have demonstrated that while the first 153 amino acids of the c-Mpl ligand are all that are required for its thrombopoietic effect in vitro,3,6,197 this truncated molecule has a markedly decreased circulatory half-life compared to the 20- to 40-h half-life of the native protein.198 Presumably, the carbohydrate-rich half of the molecule confers stability and prolongs the circulatory half-life. Similar carbohydrate sequences regulate the stability of erythropoietin.199 In addition, this part of the molecule assists in the secretion of the intact molecule from the hepatocytes by serving as a molecular chaperone or guide in protein folding; truncated muteins of this portion of the molecule have diminished secretion.200
There is a single copy of the gene for thrombopoietin on human chromosome 3q27-28.195,196,201 The gene spans approximately 7 kb with seven exons, the first two of which are noncoding. The third exon contains part of the 5′-untranslated mRNA sequence and part of the signal peptide. The erythropoietin-like region is coded for by exons 4 to 7, and all of the carbohydrate domain is encoded by exon 7. Comparison with the erythropoietin gene shows conservation of the boundaries of the coding exons except for the addition of the carbohydrate domain sequence in the final exon of the thrombopoietin gene. In addition to the functional mRNA encoded (TPO-1), two other nonfunctional m-RNA sequences (TPO-2 and TPO-3) are present due to alternative splicing.195,196
THE THROMBOPOIETIN RECEPTOR
It is now known that the thrombopoietin receptor (c-Mpl) is present on platelets and megakaryocytes, and at lesser density on most other hematopoietic precursor cells. Upon binding to thrombopoietin, the receptor undergoes dimerization, resulting in a number of signal transduction events that improve cell viability, promote growth, and possibly increase differentiation.202 In addition, receptor binding provides the major mechanism by which thrombopoietin is removed from the circulation by platelets and possibly megakaryocytes.2,203,204 and 205 Upon binding thrombopoietin, the receptor-ligand complex undergoes internalization, and the bound thrombopoietin is degraded.206 The receptor is not reexpressed on the surface.207
THE EFFECTS OF THROMBOPOIETIN IN VITRO
Binding of thrombopoietin to its receptor prevents apoptosis of megakaryocytes208 and increases their number, size, and ploidy. The rate of cellular maturation is probably also increased. These events are mediated via signal transduction pathways involving JAK, STAT, and other intracellular mediators.209,210,211,212,213,214,215,216 and 217 Addition of thrombopoietin to CD34+ cells can actually result in the majority of cells becoming megakaryocytes and then shedding platelets.218
Although thrombopoietin stimulates early precursor cells of all lineages as well as pluripotential stem cells,219 it stimulates late maturation only in megakaryocytes.
THE EFFECTS OF THROMBOPOIETIN IN VIVO
When administered to normal animals, thrombopoietin stimulates an increase in bone marrow and peripheral blood meg-CFC, an increase in bone marrow megakaryocytes, and a rise in the platelet count.220,221 and 222 Interestingly, both erythroid and multipotential precursor cells are also increased in the bone marrow and peripheral blood, but without affecting the erythrocyte or neutrophil count.
Following the daily administration of a recombinant form of thrombopoietin to normal baboons, a predictable response occurs.221,222 During the first 4 days of administration, bone marrow megakaryocyte ploidy rises to a maximum, but there is no change in the platelet count. On day 5 the platelet count begins to rise and does so at a dose-dependent rate. With continued administration of thrombopoietin, a dose-dependent plateau platelet count is attained on days 8 to 12. There is a log-linear relationship between the thrombopoietin dose and the plateau platelet count, with a maximum sixfold increase in the rate of platelet production. Upon stopping the growth factor, the platelet count returns to its baseline over 10 days without a rebound thrombocytopenia. In humans a similar time course and platelet response have been demonstrated with no acute toxicity220 but with subsequent studies indicating the potential of individuals to make antibodies to at least one of the thrombopoietin preparations under development (see Recombinant Thrombopoietic Growth Factors and Their Clinical Uses, below).
In addition to increasing the number of megakaryocytes and platelets, thrombopoietin can also affect the function of platelets. When thrombopoietin binds to its platelet receptor, it induces phosphorylation of the c-Mpl receptor and a number of other molecules in several different signal transduction pathways223,224 and 225 but does not directly cause platelet activation. However, such thrombopoietin treatment reduces by 50 percent the threshold for activation by other platelet agonists like ADP and collagen. It is unclear if this is a clinically relevant effect.
THE ROLE OF THROMBOPOIETIN IN NORMAL PHYSIOLOGY
THROMBOPOIETIN IS THE ONLY PHYSIOLOGICALLY RELEVANT REGULATOR OF PLATELET PRODUCTION
Thrombopoietin serves to “amplify” the basal production rate of megakaryocytes and platelets. When thrombopoietin or its receptor has been “knocked out” by homologous recombination in mice,226,227 and 228 the megakaryocyte and platelet mass are reduced to about 10 percent of normal, but the animals are healthy and do not spontaneously bleed. The neutrophil and erythrocyte counts are normal. In animals in which only one of the thrombopoietin genes has been deleted, the platelet count is reduced to about 65 percent of normal. However, such thrombopoietin-deficient mice can increase their platelet count if treated with other thrombopoietic growth factors such as IL-6, IL-11, or stem cell factor.229
THROMBOPOIETIN AFFECTS BONE MARROW PRECURSOR CELLS OF ALL LINEAGES
In the animals made deficient in thrombopoietin or c-Mpl, the megakaryocyte precursor cells (meg-CFC) are reduced by 90 to 95 percent, as expected. However, the myeloid and erythroid precursor cells are also reduced by 60 to 80 percent.226,229 Presumably the normal neutrophil and erythrocyte counts in these animals are maintained by the intact feedback mechanisms mediated by G-CSF and erythropoietin.
THERE IS NO “SENSOR” OF THE PLATELET MASS
Hepatic thrombopoietin production is constitutive, and the circulating levels are determined by the circulating platelet mass (Fig. 110-6). While the production of red blood cells is regulated by a cytochrome P-450 system that senses changes in oxygen delivery to tissues and alters the rate of transcription of the erythropoietin gene, thrombopoietin mRNA is produced at the same rate in normal and thrombocytopenic individuals.2,203,204 and 205,230,231 No drug or clinical condition has yet been shown to increase hepatic thrombopoietin production. Platelets and megakaryocytes contain high-affinity thrombopoietin receptors (c-Mpl) that bind and clear thrombopoietin from the circulation and thereby directly determine the circulating thrombopoietin level. When platelet production is decreased, clearance of thrombopoietin is reduced and levels rise. This type of feedback system is not unusual in hematology. Indeed, both M-CSF and G-CSF are normally regulated primarily by the amount of circulating monocytes and neutrophils, respectively.232,233 It appears that only for erythropoietin is there a true sensor of the circulating blood cell mass that in turn alters production of this hematopoietic growth factor.

FIGURE 110-6 The mechanism by which thrombopoietin (TPO) regulates platelet production from megakaryocytes. TPO (width of arrows indicates relative concentration) is produced at a constant rate by the liver and enters the circulation. Left side: When the platelet count is normal, high-affinity TPO receptors on the platelet clear most of the TPO and produce a normal plasma TPO concentration, thereby providing basal stimulation of bone marrow megakaryocytes and a normal rate of platelet production. Right side: When platelet production and the platelet count are low, the overall clearance of TPO is reduced, subsequently increasing the plasma TPO concentration and megakaryocyte and platelet production. Modified from reference 2.

MEGAKARYOCYTES IN DISEASE
As initially described in 1910,65 characteristic changes in megakaryocytes are associated with several disease processes. Most of these clinical conditions have been extensively studied with bone marrow and platelet kinetic studies10 and thrombopoietin levels.234
MEGAKARYOCYTE HYPOPLASIA SECONDARY TO CHEMOTHERAPY
The thrombocytopenia that follows chemotherapy is due to a decreased number of megakaryocytes. This results in elevated levels of thrombopoietin235 that increase the average ploidy of the remaining megakaryocytes in an effort to increase platelet production. Platelet kinetic studies have also demonstrated some element of ineffective platelet production (ineffective thrombopoiesis) in this setting.10
PERNICIOUS ANEMIA (SEE Chap. 37)
In severe pernicious anemia the low platelet count is associated with a marked increase in the number of megakaryocytes but diminished ploidy resulting in an expanded megakaryocyte mass but reduced platelet production per megakaryocyte.10 This ineffective platelet production from the megakaryocytes is comparable to the ineffective erythrocyte production also seen in this disorder.
CONGESTIVE SPLENOMEGALY (SEE Chap. 59)
As suggested above, the thrombocytopenia seen in splenomegaly secondary to liver disease has long been felt to be due to a redistribution of the normal circulating mass of platelets from the circulation to the spleen.180,236 Platelet kinetic studies have analyzed this situation further and demonstrated that the modest thrombocytopenia is not accompanied by a decrease in platelet survival but does give rise to a small increase in the number and ploidy of megakaryocytes and a small overall increase in platelet production.10 These results are at odds with data showing a reduced level of thrombopoietin and a reduction in platelet production rates in patients with cirrhosis.237
THROMBOCYTOPENIA ASSOCIATED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) (SEE Chap. 114)
Thrombocytopenia is commonly seen in both early and late HIV infection and has been considered due to immune complex binding to platelet Fc receptors and consequent platelet removal by the spleen.238 Antiretroviral treatment is often associated with improvement. However, platelet kinetic studies suggest that platelet survival is only slightly reduced, and there is marked ineffective production of platelets from megakaryocytes.139,239 In the thrombocytopenic HIV-infected patients studied,239 megakaryocyte mass and megakaryocyte size were increased two- to threefold, but the total effective platelet production from the megakaryocytes was not increased. Administration of a recombinant thrombopoietin to these patients resulted in no change in megakaryocyte mass but did increase the effective production rate eightfold and increased the platelet count from 42 × 109/liter to 349 × 109/liter.
IDIOPATHIC THROMBOCYTOPENIC PURPURA (SEE Chap. 114)
In animal models and in humans, chronic ITP is characterized by an increase in the number, size, and ploidy of bone marrow megakaryocytes. One interpretation of these findings is that the decline in platelets in ITP results in an initial rise in thrombopoietin levels, which in turn stimulates an increase in the megakaryocytes. Support for this comes from platelet kinetic studies in which these morphological findings are associated with a sixfold increase in the rate of platelet production10,240,241 and a shortened platelet survival time. However, subsequent platelet kinetic studies242 have failed to demonstrate an increase in platelet production in ITP and suggest that the morphological findings might be related to ineffective platelet production akin to that described for HIV infection. The observation that thrombopoietin levels are normal in this patient group is consistent with either hypothesis.234,243
REACTIVE THROMBOCYTOSIS (SEE Chap. 115)
Reactive thrombocytosis occurs in association with iron deficiency, malignancy, and inflammatory states. It is associated with an increased number of megakaryocytes but with ploidy less than normal, an increased megakaryocyte mass, and an increased rate of platelet production. The increased platelet count is probably secondary to the expansion of the megakaryocyte number due to inflammatory cytokines such as IL-6,244 and ploidy is reduced due to a decreased level of thrombopoietin secondary to increased thrombopoietin clearance by the expanded platelet mass.
ESSENTIAL THROMBOCYTHEMIA (SEE Chap. 115)
Although the clonal nature of essential thrombocythemia has been challenged,245 in essential thrombocythemia and the related myeloproliferative disorders such as chronic myeloid leukemia and polycythemia vera, there is a proliferation of megakaryocytes that are of high ploidy and actively produce platelets. Whether the normal regulatory mechanism via thrombopoietin and its receptor is functioning is unclear. Platelet kinetic data suggest the proliferation is autonomous of thrombopoietin in that at increased platelet mass there is a greatly increased megakaryocyte ploidy despite a normal thrombopoietin level.234,246 Evidence suggests that platelet and possibly megakaryocyte thrombopoietin receptors are decreased tenfold in essential thrombocythemia.246
MYELODYSPLASTIC SYNDROMES (SEE Chap. 90)
Thrombocytopenia as well as thrombocytosis are found in myelodysplastic syndromes and attributed to abnormal megakaryocytes. The morphological picture is that of an increased number of small megakaryocytes of low ploidy, occasionally displaying a characteristic “pawn ball” nucleus with three lobes.247 Platelet kinetic studies10 have demonstrated a greatly expanded megakaryocyte mass (increased number of megakaryocytes of low ploidy) and ineffective platelet production from the megakaryocytes.
HEMATOPOIETIC DISORDERS ASSOCIATED WITH ABNORMAL CHROMOSOME 3q
A number of hematopoietic disorders associated with thrombocythemia or abnormal megakaryocyte formation have been associated with defects involving chromosome 3q,248 and some myeloid leukemias associated with thrombocytosis have a characteristic rearrangement of chromosome 3q21 and 3q26.201 Since the thrombopoietin gene is located on chromosome 3q27-28, it has been suggested that the thrombopoietin gene might be mediating these effects.195,196,201 However, analysis of the chromosome regions in these patients has not demonstrated involvement of the thrombopoietin gene, and blood thrombopoietin levels are normal.201,249 These results suggest that other genes close to the thrombopoietin gene may be responsible for other aspects of megakaryocyte differentiation and growth.
AGNOGENIC MYELOFIBROSIS WITH MYELOID METAPLASIA (SEE Chap. 93)
The typical finding in this myeloproliferative disorder is an increase in bone marrow megakaryocytes without dysplasia as well as a large amount of fibrosis. The fibrotic response is a polyclonal proliferation of fibroblasts which has been attributed to the release of mesenchymal growth factors such as platelet-derived growth factor or transforming growth factor–b from the abnormal megakaryocytes. Subsequent data suggest that this may not be the entire mechanism.250 Overexpression of the thrombopoietin gene using adenovectors in immunodeficient SCID mice results in thrombocytosis, increased marrow megakaryocytes, fibrosis, and extramedullary hematopoiesis that mimics the clinical disorder. However, similar overexpression of thrombopoietin in NOD-SCID mice (which have reduced monocyte and macrophage function in addition to the lymphocyte deficiency in SCID mice) produced similar thrombocytosis and megakaryocytosis but no fibrosis. These results imply that other monocyte/macrophage mediators may be involved in causing the fibrosis.
DISORDERS OF THROMBOPOIETIN PRODUCTION
The thrombopoietin physiology described above suggests possible mechanisms for clinical disorders associated with abnormalities in platelet count.231 A few of these postulated disorders have been identified.
INHERITED THROMBOCYTHEMIA
A few families have been described that have a disorder that is clinically like the more common, sporadic cases of essential thrombocythemia.251,252 Analysis of one of these families252 identified a single point mutation in the splice donor site of intron 3 of the thrombopoietin gene that produced a new thrombopoietin mRNA with a normal protein coding region but with a shortened 5′ untranslated region that was more efficiently translated than the normal thrombopoietin transcripts. The 5′ untranslated region of thrombopoietin mRNA is unusual in that it contains numerous translation initiation sites, only one of which produces the active protein. A reduction in the number of these alternative translation initiation sites yields thrombopoietin mRNA that is more efficiently translated.253 In the families with inherited thrombocythemia, loss of these sites by mutation results in more thrombopoietin protein synthesis, higher plasma thrombopoietin levels, and chronically elevated platelet counts. In individuals with the more common, sporadic cases of essential thrombocythemia none of these mutations have been found.
LIVER DISEASE
Since the liver is the primary site of thrombopoietin production,254 and the thrombopoietin gene is apparently not inducible, thrombopoietin deficiency may be potentially responsible (along with splenic sequestration) for the thrombocytopenia in patients with liver failure. In animals, partial resection of the liver results in a proportional decrease in the platelet count.255 In patients with liver failure, thrombopoietin levels appear to be inappropriately low,237 leading to the suggestion that recombinant forms of thrombopoietin may be an effective therapy.
RECOMBINANT THROMBOPOIETIC GROWTH FACTORS AND THEIR CLINICAL USES
THROMBOPOIETIN
Two recombinant thrombopoietins have been extensively studied and demonstrate some clinical effect. One is a glycosylated molecule produced in Chinese hamster ovary (CHO) cells consisting of the full-length, native human amino acid sequence (recombinant thrombopoietin, rHuTPO) which has a circulatory half-life of 20 to 40 h.256,257 and 258 The other is a nonglycosylated, truncated molecule produced in E. coli composed of the first 163 amino acids of the native molecule and chemically coupled on the amino terminus to polyethylene glycol (pegylated, recombinant megakaryocyte growth and development factor, PEG-rHuMGDF).220,259,260 The half of the native thrombopoietin molecule contained in the latter drug is 50 percent similar to erythropoietin and contains all of the receptor-binding domain of thrombopoietin; it has a very short circulatory half-life and thus little biological activity in vivo. The addition of the polyethylene glycol moiety serves to stabilize the molecule in the circulation and replaces the domain that normally confers longer intravascular survival. The polyethylene glycol-thrombopoietin conjugate has a half-life of 30 to 40 h. Neither recombinant thrombopoietin product has received approval for clinical use. Some patients given PEG-rHuMGDF subcutaneously have developed antibodies to the molecule that cross-react to the endogenous thrombopoietin and cause thrombocytopenia. Intravenous administration of PEG-rHuMGDF has not been associated with antibody formation, and development of PEG-rHuMGDF by this route continues.
These recombinant thrombopoietins have demonstrated some benefit in the primary prophylaxis of thrombocytopenia associated with chemotherapy by reducing the duration, and often the depth, of the thrombocytopenia.257,259,260 In addition, they may decrease the need for platelet transfusions.257 However, when used in myeloablative chemotherapy settings such as AML261 or stem cell transplantation,262,263 and 264 neither has shown significant benefit. Both are potent mobilizers of peripheral blood progenitor cells260 and can expand cord blood progenitor cells ex vivo.265 Both can stimulate an increase in platelet count in normal platelet donors and increase the yield of plateletpheresis.266,267 Platelet counts in thrombocytopenic HIV-infected patients can also be increased.239,268
INTERLEUKIN-11
IL-3, IL-6, and IL-11 produce significant stimulation of platelet production. IL-3 and IL-6 are probably too toxic for most clinical uses, but recombinant IL-11 has modest side effects and has been approved by the FDA for use in the prevention of chemotherapy-induced thrombocytopenia.269 Recombinant human IL-11 (Neumega) stimulates megakaryocyte growth and increases platelet production with a time course similar to that of thrombopoietin. Its thrombopoietic action is not mediated through thrombopoietin release or synergism and is independent of the thrombopoietin receptor.123 Surprisingly, when the gene for the IL-11 receptor was eliminated in mice, there was no effect on the production of platelets or any other blood cell, suggesting that IL-11 is not important for normal hematopoiesis.270,271 However, in clinical studies IL-11 reduced the extent of chemotherapy-induced thrombocytopenia123,269 and in one study actually reduced the need for platelet transfusions by 27 percent.124 Its major side effects are dilutional anemia, pleural effusions, and atrial arrhythmias.
OTHER THROMBOPOIETIC GROWTH FACTORS
There is also a growing number of other molecularly designed platelet growth factors based on the structure of thrombopoietin or its receptor that are just entering preclinical testing. One of these, promegapoietin,272 is a molecular modification of thrombopoietin in which the receptor-binding region is coupled to the hematopoietic growth factor IL-3. This molecule can bind to and activate both the thrombopoietin and IL-3 receptor. Another is a thrombopoietin peptide mimetic (TPO peptide mimetic) that consists of a dimer of two identical 14–amino acid peptides with no sequence homology to thrombopoietin and that avidly binds to and activates the thrombopoietin receptor, c-Mpl.273 Neither of these molecules has entered clinical testing. These molecules define a new and growing family of molecules called the Mpl ligand family274 based on their common ability to bind and activate the receptor for thrombopoietin, c-Mpl.
Novel molecularly designed proteins275 currently under development include myelopoietin (an IL-3 receptor agonist) and progenipoietin-G (a fusion protein of flt-3 ligand and G-CSF)276; they both stimulate platelet production as well as cells of other lineages and give the promise of being “panpoietins.”
CHAPTER REFERENCES

1.
Wright JH: The origin and nature of blood plates. Boston Med Surg J 154:643, 1906.

2.
Kuter DJ, Beeler DL, Rosenberg RD: The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 91:11104, 1994.

3.
De Sauvage FJ, Hass PE, Spencer SD, et al: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 369:533, 1994.

4.
Kato T, Ogami K, Shimada Y, et al: Purification and characterization of thrombopoietin. J Biochem 118:229, 1995.

5.
Lok S, Kaushansky K, Holly RD, et al: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369:565, 1994.

6.
Bartley TD, Bogenberger J, Hunt P, et al: Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 77:1117, 1994.

7.
Kaushansky K: Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost 74:521, 1995.

8.
Levin J: The evolution of mammalian platelets, in Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology, edited by DJ Kuter, P Hunt, W Sheridan, D Zucker-Franklin, p 63. Humana Press, Ottowa, 1997.

9.
Wright JH: A rapid method for the differential staining of blood films and malarial parasites. J Med Res 7:138, 1902.

10.
Harker LA, Finch CA: Thrombokinetics in man. J Clin Invest 48:963, 1969.

11.
Kuter DJ, Greenberg SM, Rosenberg RD: Analysis of megakaryocyte ploidy in rat bone marrow cultures. Blood 74:1952, 1989.

12.
Jackson CW, Brown LK, Somerville BC, et al: Two-color flow cytometric measurement of DNA distributions of rat megakaryocytes in unfixed, unfractionated marrow cell suspensions. Blood 63:768, 1984.

13.
Hegyi E, Nakazawa M, Debili N, et al: Developmental changes in human megakaryocyte ploidy. Exp Hematol 19:87, 1991.

14.
Jackson CW: Megakaryocyte endomitosis: a review. Int J Cell Cloning 8:224, 1990.

15.
Radley J, Green S: Ultrastructure of endomitosis in megakaryocytes. Nouv Rev Fr Hematol 31:232a, 1989.

16.
Nagata Y, Muro Y, Todokoro K: Thrombopoietin-induced polyploidization of bone marrow megakaryocytes is due to a unique regulatory mechanism in late mitosis. J Cell Biol 139:449, 1997.

17.
Paulus JM, Prenant M, Deschamps JF, Henry-Amar M: Polyploid megakaryocytes develop randomly from a multicompartmental system of committed progenitors. Proc Nat Acad Sci USA 79:4410, 1982.

18.
Zimmet JM, Ladd D, Jackson CW, et al: A role for cyclin D3 in the endomitotic cell cycle. Mol Cell Biol 17:7248, 1997.

19.
Zhang Y, Wang Z, Liu DX, et al: Ubiquitin-dependent degradation of cyclin B is accelerated in polyploid megakaryocytes. J Biol Chem 273:1387, 1998.

20.
Zimmet JM, Toselli P, Ravid K: Cyclin D3 and megakaryocyte development: exploration of a transgenic phenotype. Stem Cells 16(Suppl 2): 97, 1998.

21.
Jones O: Origin of megakaryocyte granules from Golgi vesicles. Anat Rec 138:105, 1960.

22.
Behnke O, Pedersen NT: Ultrastructural aspects of megakaryocyte maturation and platelet release, in Platelets: Production, Function, Transfusion, and Storage, edited by MG Baldini, S Ebbe, p 21. Grune & Stratton, New York, 1974.

23.
Vinci G, Tabilio A, Deschamps JF, et al: Immunological study of in vitro maturation of human megakaryocytes. Br J Haematol 56:589, 1984.

24.
White JG: Tubular elements in platelet granules. Blood 32:148, 1968.

25.
Cramer EM, Meyer D, le Menn R, Breton-Gorius J: Eccentric localization of von Willebrand factor in an internal structure of platelet alpha-granule resembling that of Weibel-Palade bodies. Blood 66:710, 1985.

26.
Wencel-Drake JD, Painter RG, Zimmerman TS, Ginsberg MH: Ultrastructural localization of human platelet thrombospondin, fibrinogen, fibronectin, and von Willebrand factor in frozen thin section. Blood 65:929, 1985.

27.
Suzuki H, Katagirl Y, Tsukita S, et al: Location of adhesive proteins in two newly subdivided zones in electron-lucent matrix of human a-granules. Histochemistry 94:337, 1990.

28.
Sander HJ, Slot JW, Bouma BN, et al: Immunocytochemical localization of fibrinogen, platelet factor 4, and beta thromboglobulin in thin frozen sections of human blood platelets. J Clin Invest 72:1277, 1983.

29.
Hegyi E, Nakeff A: Ultrastructural localization of platelet factor 4 in rat megakaryocytes and platelets by gold-labeled antibody detection. Exp Hematol 17:223, 1989.

30.
Harrison P, Savidge GF, Cramer EM: The origin and physiological relevance of alpha-granule adhesive proteins. Br J Haematol 74:125, 1990.

31.
Greenberg SM, Kuter DJ, Rosenberg RD: In vitro stimulation of megakaryocyte maturation by megakaryocyte stimulatory factor. J Biol Chem 262:3269, 1987.

32.
Handagama PJ, Shuman MA, Bainton DF: The origin of platelet a-granule protein, in Molecular Biology and Differentiation of Megakaryocytes, edited by J Breton-Gorius, J Levin, AT Nurden, N Williams, p 119. Wiley-Liss, New York, 1990.

33.
Handagama PJ, Bainton DF, Jacques Y, et al: Kistrin, an integrin antagonist, blocks endocytosis of fibrinogen into guinea pig megakaryocyte and platelet a-granules. J Clin Invest 91:193, 1993.

34.
Handagama PJ, Amrani DL, Shuman MA: Endocytosis of fibrinogen into hamster megakaryocyte a-granules is dependent on dimeric gamma A configuration. Blood 85:1790, 1995.

35.
Harrison P, Wilbourn B, Debili N, et al: Uptake of plasma fibrinogen into alpha granules of human megakaryocytes and platelets. J Clin Invest 84:1320, 1989.

36.
Handagama PJ, Shuman MA, Bainton DF: Incorporation of intravenously injected albumin, immunoglobulin G, and fibrinogen in guinea pig megakaryocyte granules. J Clin Invest 84:73, 1989.

37.
Lichtman MA, Chamberlain JK, Simon W, Santillo PA: Parasinusoidal location of megakaryocytes in marrow: a determinant of platelet release. Am J Hematol 4:303, 1978.

38.
Cramer EM, Savidge GF, Vainchenker W, et al: Alpha-granule pool of glycoprotein IIb-IIIa in normal and pathologic platelets and megakaryocytes. Blood 75:1220, 1990.

39.
Stenberg PE, McEver RP, Shuman MA, et al: A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 101:880, 1985.

40.
Metzelaar MJ, Heijnen HF, Sixma JJ, Nieuwenhuis HK: Identification of a 33-kd protein associated with the alpha-granule membrane (GMP-33) that is expressed on the surface of activated platelets. Blood 79:372, 1992.

41.
Breton-Gorius J, Clezardin P, Guichard J, et al: Localization of platelet osteonectin at the internal face of the alpha-granule membranes in platelets and megakaryocytes. Blood 79:936, 1992.

42.
Da Prada M, Richard SJG, Kettler R: Amine storage organelles in platelets, in Platelets in Biology and Pathology, edited by AS Gordon, p 107. Elsevier/North Holland, Amsterdam, 1981.

43.
White JG: Serotonin storage organelles in human megakaryocytes. Am J Pathology 63:403, 1971.

44.
Schick PK, Weinstein M: A marker for megakaryocytes: serotonin accumulation in guinea pig megakaryocytes. J Lab Clin Med 98:607, 1981.

45.
Bricker LJ, Zuckerman KS: Serotonin uptake by progeny of murine megakaryocyte precursors (CFU-M) in vitro. Exp Hematol 12:672, 1984.

46.
Gerrard JM, Lint D, Sims PJ, et al: Identification of a platelet dense granule membrane protein that is deficient in a patient with the Hermansky-Pudlak syndrome. Blood 77:101, 1991.

47.
Israels SJ, Gerrard JM, Jacques YV, et al: Platelet dense granule membranes contain both granulophysin and P-selectin (GMP-140). Blood 80:143, 1992.

48.
Bentfeld-Barker ME, Bainton DF: Identification of primary lysosomes in human megakaryocytes and platelets. Blood 59:472, 1982.

49.
Sixma JJ, van den Berg A, Hasilik A, et al: Immuno-electron microscopical demonstration of lysosomes in human blood platelets and megakaryocytes using anti-cathepsin D. Blood 65:1287, 1985.

50.
Metzelaar MJ, Clevers HC: Lysosomal membrane glycoproteins in platelets. Thromb Haemost 68:378, 1992.

51.
Breton-Gorius J, Guichard J: Two different types of granules in megakaryocytes and platelets as revealed by the diaminobenzidine method. J Microsc Biol Cell 23:197, 1975.

52.
Behnke O: An electron microscope study of the megakaryocyte of the rat bone marrow: I. The development of the demarcation membrane system and the platelet surface coat. J Ultrastruct Res 24:412, 1968.

53.
MacPherson GG: Origin and development of the demarcation system in megakaryocytes of rat bone marrow. J Ultrastruct Res 40:167, 1972.

54.
Breton-Gorius J, Reyes F: Ultrastructure of human bone marrow cell maturation. Int Rev Cytol 46:251, 1976.

55.
Radley, JM, Haller CJ: The demarcation membrane system of the megakaryocyte: a misnomer. Blood 60:213, 1982.

56.
MacPherson GG: Changes in megakaryocyte development following thrombocytopenia. Br J Hematol 26:105, 1974.

57.
Debili N, Kieffer N, Nakazawa M, et al: Expression and isolation of a platelet GPIb-like protein in human umbilical vein endothelial cells and bovine aortic smooth muscle cells. Blood 76:368, 1990.

58.
Berridge MV, Ralph SJ, Tan AS: Cell-lineage antigens of the stem cell-megakaryocyte-platelet lineage are associated with the platelet IIb/IIIa glycoprotein complex. Blood 66:76, 1985.

59.
Debili N, Issaad C, Masse JM, et al: Expression of CD34 and platelet glycoproteins during human megakaryocytic differentiation. Blood 80:3022, 1992.

60.
Uzan G, Prenant M, Prandini MH, et al: Tissue-specific expression of the platelet GPIIb gene. J Biol Chem 266:8932, 1991.

61.
Roth GJ: Developing relationships: arterial platelet adhesion, glycoprotein Ib, and leucine-rich glycoproteins. Blood 77:5, 1991.

62.
Asch AS, Adelman B, Fujimoto M, Nachman RL: Identification and isolation of a platelet GPIb-like protein in human umbilical vein endothelial cells and bovine aortic smooth muscle cells. J Clin Invest 81:1600, 1988.

63.
Wu G, Essex DW, Meloni FJ, et al: Human endothelial cells in culture and in vitro express on their surface all four components of the glycoprotein Ib/IX/V complex. Blood 90:2660, 1997.

64.
Kelly MD, Essex DW, Shapiro SS, et al: Complementary DNA cloning of the alternatively expressed endothelial cell glycoprotein Ib beta (GPIb beta) and localization of the GPIb beta gene to chromosome 22. J Clin Invest 93:2417, 1994.

65.
Wright JH: The histogenesis of the blood platelets. J Morph 21:263, 1910.

66.
Odell TT, Jackson CW: Polyploidy and maturation of rat megakaryocytes. Blood 32:102, 1968.

67.
Williams N, Levine RF: The origin, development and regulation of megakaryocytes. Br J Haematol 52:173, 1982.

68.
Mazur EM, Hoffman R, Chasis J, et al: Immunofluorescent identification of human megakaryocyte colonies using an antiplatelet glycoprotein antiserum. Blood 57:277, 1981.

69.
Jackson CW: Cholinesterase as a possible marker for early cells of the megakaryocytic series. Blood 42:413, 1973.

70.
Long MW, Williams N, McDonald TP: Immature megakaryocytes in the mouse: in vitro relationship to megakaryocyte progenitor cells and mature megakaryocytes. J Cell Physiol 112:339, 1982.

71.
Long MW, Williams N, Ebbe S: Immature megakaryocytes in the mouse: physical characteristics, cell cycle status, and in vitro responsiveness to thrombopoietic stimulatory factor. Blood 59:569, 1982.

72.
Young KM, Weiss L: Megakaryocytopoiesis: incorporation of tritiated thymidine by small acetylcholinesterase-positive cells in murine bone marrow during antibody-induced thrombocytopenia. Blood 69:290, 1987.

73.
Rabellino EM, Nachman RL, Williams N, et al: Human megakaryocytes: I. Characterization of the membrane and cytoplasmic components of isolated marrow megakaryocytes. J Exp Med 149:1273, 1979.

74.
Vainchenker W, Deschamps JF, Bastin JM, et al: Two monoclonal antiplatelet antibodies as markers of human megakaryocyte maturation: immunofluorescent staining and platelet peroxidase detection in megakaryocyte colonies and in in vivo cells from normal and leukemic patients. Blood 59:514, 1982.

75.
Lev-Lehman E, Deutsch V, Eldor A, Soreq H: Immature human megakaryocytes produce nuclear-associated acetylcholinesterase. Blood 89:3644, 1997.

76.
Kavnoudias H, Jackson H, Ettlinger K, et al: Interleukin 3 directly stimulates both megakaryocyte progenitor cells and immature megakaryocytes. Exp Hematol 20:43, 1992.

77.
Breton-Gorius J, Gordin M, Reyes F: Ultrastructure of the leukemic cell, in The Leukemic Cell, edited by D Catovsky, p 87. Churchill Livingston, London, 1981.

78.
Long MW, Henry RL: Thrombocytosis-induced suppression of small acetylcholinesterase-positive cells in bone marrow of rats. Blood 54:1338, 1979.

79.
Rabellino EM, Levine RB, Leung LL, Nachman RL: Human megakaryocytes: II. Expression of platelet proteins in early marrow megakaryocytes. J Exp Med 154:88, 1981.

80.
Gerrard JM, White JG, Rao GH, Townsend D: Localization of platelet prostaglandin production in the platelet dense tubular system. Am J Path 83:283, 1976.

81.
Breton-Gorius J, Vainchenker W: Expression of platelet proteins during the in vitro and in vivo differentiation of megakaryocytes and morphological aspects of their maturation. Semin Hematol 23:43, 1986.

82.
Breton-Gorius J, Villeval JL, Mitjavila MT, et al: Ultrastructural and cytochemical characterization of blasts from early erythroblastic leukemias. Leukemia 1:173, 1987.

83.
Breton-Gorius J: Megakaryocyte maturation and platelet release in normal pathologic conditions, in Blood Cell Biochemistry, edited by JR Harris, p 1. Plenum, New York, 1991.

84.
Nakahata T, Ogawa M: Identification in culture of a class of hemopoietic colony-forming units with extensive capability to self-renew and generate multipotential hemopoietic colonies. Proc Natl Acad Sci USA 79:3843, 1982.

85.
Fauser AA, Messner HA: Identification of megakaryocytes, macrophages, and eosinophils in colonies of human bone marrow containing neutrophilic granulocytes and erythroblasts. Blood 53:1023, 1979.

86.
Solar GP, Kerr WG, Zeigler FC, et al: Role of c-mpl in early hematopoiesis. Blood 92:4, 1998.

87.
Orkin SH, Shivdasani RA, Fujiwara Y, McDevitt MA: Transcription factor GATA-1 in megakaryocyte development. Stem Cells 16(Suppl 2):79, 1998.

88.
Martin DI, Zon LI, Mutter G, Orkin SH: Expression of an erythroid transcription factor in megakaryocytic and mast cell lineages. Nature 344:444, 1990.

89.
Orkin SH: GATA-binding transcription factors in hematopoietic cells. Blood 80:575, 1992.

90.
Poujol C, Tronik-Le Roux D, Tropel P, et al: Ultrastructural analysis of bone marrow hematopoiesis in mice transgenic for the thymidine kinase gene driven by the aIIb promoter. Blood 92:2012, 1998.

91.
Tronik-Le Roux D, Roullot V, Schweitzer A, et al: Suppression of erythro-megakaryocytopoiesis and the induction of reversible thrombocytopenia in mice transgenic for the thymidine kinase gene targeted by the platelet glycoportein aIIb promoter. J Exp Med 181:2141, 1995.

92.
Tropel P, Roullot V, Vernet M, et al: A 2.7-kb portion of the 5′ flanking region of the murine glycoprotein aIIb is transcriptionally active in primitive hematopoietic progenitor cells. Blood 90:2995, 1997.

93.
Vigon I, Mornon J-P, Cocault L, et al: Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: Identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 89:5640, 1992.

94.
Methia N, Louache F, Vainchenker W, Wendling F: Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 82:1395, 1993.

95.
Long MW, Gragowski LL, Heffner CH, Boxer LA: Phorbol diesters stimulate the development of an early murine progenitor cell. The burst-forming unit-megakaryocyte. J Clin Invest 76:431, 1985.

96.
Briddell RA, Brandt JE, Straneva JE, et al: Characterization of the human burst-forming unit-megakaryocyte. Blood 74:145, 1989.

97.
Gewirtz AM, Hoffman R: Human megakaryocyte production: cell biology and clinical considerations. Hematol Oncol Clin North Am 4:43, 1990.

98.
Briddell RA, Hoffman R: Cytokine regulation of the human burst-forming unit-megakaryocyte. Blood 76:516, 1990.

99.
Hoffman R: Regulation of megakaryocytopoiesis. Blood 74:1196, 1989.

100.
Metcalf D, MacDonald HR, Odartchenko N, Sordat B: Growth of mouse megakaryocyte colonies in vitro. Proc Natl Acad Sci USA 72:1744, 1975.

101.
Vainchenker W, Bouguet J, Guichard J, Breton-Gorius J: Megakaryocyte colony formation from human bone marrow precursors. Blood 54:940, 1979.

102.
Miyazaki H, Inoue H, Yanagida M, et al: Purification of rat megakaryocyte colony-forming cells using a monoclonal antibody against rat platelet glycoprotein IIb/IIIa. Exp Hematol 20:855, 1992.

103.
Levine RB, Lamaziere J, Broxmeyer HE, et al: Human megakaryocytes: V. Changes in the phenotypic profile of differentiating megakaryocytes. J Exp Med 161:457, 1985.

104.
Nakeff A: Colony-forming unit, megakaryocyte (CFU-m): its use in elucidating the kinetics and humoral control of the megakaryocytic committed progenitor cell compartment, in Experimental Hematology Today, edited by SJ Baum, DG Ledney, p 111. Springer, New York, 1977.

105.
Broudy VC, Lin NL, Fox N, et al: Thrombopoietin stimulates colony-forming unit-megakaryocyte proliferation and megakaryocyte maturation independently of cytokines that signal through the gp130 receptor subunit. Blood 88:2026, 1996.

106.
Dolzhanskiy A, Basch RS, Karpatkin S: The development of human megakaryocytes: III. Development of mature megakaryocytes from highly purified committed progenitors in synthetic culture media and inhibition of thrombopoietin-induced polyploidization by interleukin-3. Blood 89:426, 1997.

107.
Choi ES, Hokom MM, Chen JL, et al: The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. Br J Haematol 95:227, 1996.

108.
Carrington PA, Hill RJ, Stenberg PE, et al: Multiple in vivo effects of interleukin-3 and interleukin-6 on murine megakaryocytopoiesis. Blood 77:34, 1991.

109.
Stahl CP, Winton EF, Monroe MC, et al: Differential effects of sequential, simultaneous, and single agent interleukin-3 and granulocyte-macrophage colony-stimulating factor on megakaryocyte maturation and platelet response in primates. Blood 80:2479, 1992.

110.
Ganser A, Lindemann A, Seipelt G, et al: Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 76:666, 1990.

111.
Kurzrock R, Talpaz M, Estrov Z, et al: Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9:1241, 1991.

112.
Ishibashi T, Kimura H, Shikama Y, et al: Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 74:1241, 1989.

113.
Ishibashi T, Kimura H, Uchida T, et al: Human interleukin-6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci USA 86:5953, 1989.

114.
Kishimoto T: The biology of interleukin-6. Blood 74:1, 1989.

115.
Imai T, Koike K, Kubo T, et al: Interleukin-6 supports human megakaryocytic proliferation and differentiation in vitro. Blood 78:1969, 1991.

116.
Kimura H, Ishibashi T, Uchida T, et al: Interleukin-6 is a differentiation factor for human megakaryocytes in vitro. Eur J Immunol 20:1927, 1990.

117.
Hill RJ, Warren MK, Levin J: Stimulation of thrombopoiesis in mice by human recombinant interleukin-6. J Clin Invest 85:1242, 1990.

118.
Asano S, Okano A, Ozawa K, et al: In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets. Blood 75:1602, 1990.

119.
Mayer P, Geissler K, Valent P, et al: Recombinant human interleukin-6 is a potent inducer of the acute phase response and elevates the blood platelets in nonhuman primates. Exp Hematol 19:688, 1991.

120.
Stahl CP, Zucker-Franklin D, Evatt BL, Winton EF: Effects of human interleukin-6 on megakaryocyte development and thrombocytopoiesis in primates. Blood 78:1467, 1991.

121.
Teramura M, Kobayashi S, Hoshino S, et al: Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 79:327, 1992.

122.
Teramura M, Kobayashi S, Yoshinaga K, et al: Effect of interleukin-11 on normal and pathological thrombopoiesis. Cancer Chemother Pharmacol 38(suppl):S99, 1996.

123.
Du X, Williams DA: Interleukin-11: Review of molecular, cell biology, and clinical use. Blood 89:3897, 1997.

124.
Tepler I, Elias L, Smith JW, et al: A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87:3607, 1996.

125.
Carlino JA, Higley HR, Creson JR, et al: Transforming growth factor beta 1 systemically modulates granuloid, erythroid, lymphoid, and thrombocytic cells in mice. Exp Hematol 20:943, 1992.

126.
Ishibashi T, Miller SL, Burstein SA: Type beta transforming growth factor is a potent inhibitor of murine megakaryocytopoiesis in vitro. Blood 69:1737, 1987.

127.
Kuter DJ, Gminski DM, Rosenberg RD: Transforming growth factor b inhibits megakaryocyte growth and endomitosis. Blood 79:619, 1992.

128.
Bellucci S, Han ZC, Caen JP: Positive and negative regulation of megakaryocytopoiesis. C R Seances Soc Biol Fil 190:515, 1996.

129.
Gugliotta L, Bagnara GP, Catani L, et al: In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia. Br J Haematol 71:177, 1989.

130.
Han ZC, Bellucci S, Caen JP: Regulation of human megakaryocytopoiesis. Nouv Rev Fr Hematol 32:395, 1990.

131.
Han ZC, Bellucci S, Caen JP: Megakaryocytopoiesis: characterization and regulation in normal and pathologic states. Int J Hematol 54:3, 1991.

132.
Hassan HT, Freund M: Characteristic biological features of human megakaryoblastic leukaemia cell lines. Leuk Res 19:589, 1995.

133.
Hassan HT, Drexler HG: Interleukins and colony stimulating factors in human myeloid leukemia cell lines. Leuk Lymphoma 20:1, 1995.

134.
Muraoka K, Tsuji K, Yoshida M, et al: Thrombopoietin-independent effect of interferon-gamma on the proliferation of human megakaryocyte progenitors. Br J Haematol 98:265, 1997.

135.
Gisslinger H, Chott A, Scheithauer W, et al: Interferon in essential thrombocythaemia. Br J Haematol 79 (Suppl) 1:42, 1991.

136.
Murphy S, Peterson P, Iland H, Laszlo J: Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34:29, 1997.

137.
Shiota G, Okubo M, Kawasaki H, Tahara T: Interferon increases serum thrombopoietin in patients with chronic hepatitis C. Br J Haematol 97:340, 1997.

138.
Chernoff A, Levine RF, Goodman DS: Origin of platelet-derived growth factor in megakaryocytes in guinea pigs. J Clin Invest 65:926, 1980.

139.
Ballem PJ, Belzberg A, Devine DV, et al: Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med 327:1779, 1992.

140.
Yamada F: The fine structure of the megakaryocyte in the mouse spleen. Acta Anat 29:267, 1957.

141.
Becker RP, De Bruyn PPH: The transmural passage of blood cells into myeloid sinusoids and the entry of platelets into the sinusoidal circulation; a scanning electron microscopic investigation. Am J Anat 145:183, 1975.

142.
Behnke O: An electron microscope study of the rat megacaryocyte: II. Some aspects of platelet release and microtubules. J Ultrastruct Res 26:111, 1969.

143.
Radley JM, Scurfield G: The mechanism of platelet release. Blood 56:996, 1980.

144.
Tong M, Seth P, Penington DG: Proplatelets and stress platelets. Blood 69:522, 1987.

145.
Topp KS, Tablin F, Levin J: Culture of isolated bovine megakaryocytes on reconstituted basement membrane matrix leads to proplatelet process formation. Blood 76:912, 1990.

146.
Leven RM, Tablin F: Extracellular matrix stimulation of guinea pig megakaryocyte proplatelet formation in vitro is mediated through the vitronectin receptor. Exp Hematol 20:1316, 1992.

147.
Hunt P, Hokom MM, Wiemann B, et al: Megakaryocyte proplatelet-like process formation in vitro is inhibited by serum prothrombin, a process which is blocked by matrix-bound glycosaminoglycans. Exp Hematol 21:372, 1993.

148.
Lecine P, Blank V, Shivdasani R: Characterization of the hematopoietic transcription factor NF-E2 in primary murine megakaryocytes. J Biol Chem 273:7572, 1998.

149.
Lecine P, Villeval J, Vyas P, et al: Mice lacking transcription factor NF-E2 provide in vivo validation of the proplatelet model of thrombocytopoiesis and show a platelet production defect that is intrinsic to megakaryocytes. Blood 92:1608, 1998.

150.
Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH: A lineage-specific knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J 16:3965, 1997.

151.
Kaufman RM, Airo R, Pollack S, Crosby WH: Circulating megakaryocytes and platelet release in the lung. Blood 26:720, 1965.

152.
Trowbridge EA, Martin JF, Slater DN: Evidence for a theory of physical fragmentation of megakaryocytes, implying that all platelets are produced in the pulmonary circulation. Thromb Res 28:461, 1982.

153.
Pedersen NT: Occurrence of megakaryocytes in various vessels and their retention in the pulmonary capillaries in man. Scand J Haematol 21:369, 1978.

154.
Tavassoli M, Aoki M: Migration of entire megakaryocytes through the marrow-blood barrier. Br J Haematol 48:25, 1981.

155.
Martin JF, Slater DN, Trowbridge EA: Evidence that platelets are produced in the pulmonary circulation by a physical process. Prog Clin Biol Res 215:405, 1986.

156.
Levine RF, Eldor A, Shoff PK, et al: Circulating megakaryocytes: delivery of large numbers of intact, mature megakaryocytes to the lungs. Eur J Haematol 51:233, 1993.

157.
Corash L, Mok Y, Levin J, Baker G: Regulation of platelet heterogeneity: effects of thrombocytopenia on platelet volume and density. Exp Hematol 18:205, 1990.

158.
Frojmovic MM, Milton JG: Human platelet size, shape, and related functions in health and disease. Physiol Reviews 62:185, 1982.

159.
Garg SK, Amorosi EL, Karpatkin S: Use of the megathrombocyte as an index of megakaryocyte number. N Engl J Med 284:11, 1971.

160.
Corash L, Chen HY, Levin J, et al: Regulation of thrombopoiesis: effects of the degree of thrombocytopenia on megakaryocyte ploidy and platelet volume. Blood 70:177, 1987.

161.
Cole JL, Marzec UM, Gunthel CJ, et al: Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients. Blood 91:3239, 1998.

162.
Giles C: The platelet count and mean platelet volume. Br J Haematol 48:31, 1981.

163.
Garg SK, Lackner H, Karpatkin S: The increased percentage of megathrombocytes in various clinical disorders. Ann Intern Med 77:361, 1972.

164.
Karpatkin S: Biochemical and clinical aspects of megathrombocytes. Ann N Y Acad Sci 201:262, 1972.

165.
Karpatkin S, Garg SK: The megathrombocyte as an index of platelet production. Br J Haematol 26:307, 1974.

166.
Chatterji AK, Lynch EC, Garg SK, et al: Circulating large platelets. N Engl J Med 284:1440, 1971.

167.
van der Loo B, Martin JF: Megakaryocytes and platelets in vascular disease. Baillieres Clin Haematol 10:109, 1997.

168.
Ulich TR, del Castillo J, Senaldi G, et al: Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 87:5006, 1996.

169.
Daw NC, Arnold JT, Abushullaih BA, et al: A single intravenous dose of murine megakaryocyte growth and development factor potently stimulates platelet production, challenging the necessity for daily administration. Blood 91:466, 1998.

170.
O’Malley CJ, Rasko JE, Basser RL, et al: Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 88:3288, 1996.

171.
Fujiwara Y, Browne CP, Cunniff KC, et al: Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl Acad Sci USA 93:12355, 1996.

172.
Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, et al: Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 81:695, 1995.

173.
Shivdasani RA, Orkin SH: Erythropoiesis and globin gene expression in mice lacking the transcription factor NF-E2. Proc Natl Acad Sci USA 92:8690, 1995.

174.
Lecine P, Shivdasani RA: Cellular and molecular biology of megakaryocyte differentiation in the absence of lineage-restricted transcription factors. Stem Cells 16(Suppl 2):91, 1998.

175.
Kuter DJ: The physiology of platelet production. Stem Cells 14(Suppl 1): 88, 1996.

176.
Brecher G, Cronkite E: Morphology and enumeration of human blood platelets. J Appl Physiol 3:365, 1950.

177.
Bessman JD, Williams LJ, Gilmer PR: The inverse relation of platelet size and count in normal subjects and an artifact of other particles. Am J Clin Pathol 76:289, 1981.

178.
Thompson CB: From precursor to product; how do megakaryocytes produce platelets, in Megakaryocyte Development and Function, edited by RF Levine, N Williams, J Levin, B Evatt, p 361. Liss, New York, 1986.

179.
Von Behrens WE: Evidence of phylogenetic canalization of the circulating platelet mass in man. Thromb Diath Haemorrh 27(suppl):159, 1972.

180.
Aster RH: Pooling of platelets in the spleen: role in the pathogenesis of “hypersplenic” thrombocytopenia. J Clin Invest 45:645, 1966.

181.
De Gabriele G, Penington DG: Regulation of platelet production: “hypersplenism” in the experimental animal. Br J Haematol 13:383, 1967.

182.
Aster RH: Studies of the mechanism of “hypersplenic” thrombocytopenia in rats. J Lab Clin Med 70:736, 1967.

183.
Kuter DJ, Rosenberg RD: Regulation of megakaryocyte ploidy in vivo in the rat. Blood 75:74, 1990.

184.
Penington DG, Olsen TE: Megakaryocytes in states of altered platelet production: cell numbers, size and DNA content. Br J Haematol 18:447, 1970.

185.
Burstein SA, Adamson JW, Erb SK, Harker LA: Megakaryocytopoiesis in the mouse: response to varying platelet demand. J Cell Physiol 109:333, 1981.

186.
Levin J, Levin FC, Metcalf D: The effects of acute thrombocytopenia on megakaryocyte-CFC and granulocyte-macrophage-CFC in mice: studies of bone marrow and spleen. Blood 56:274, 1980.

187.
Kelemen E, Cserhati I, Tanos B: Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol 20:350, 1958.

188.
Kato T, Ogami K, Shimada Y, et al: Purification and characterization of thrombopoietin. J Biochem 119:229, 1995.

189.
Souryi M, Vigon I, Penciolelli J-F, et al: A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 63:1137, 1990.

190.
Wendling F, Maraskovsky E, Debili N, et al: c-Mpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 369:571, 1994.

191.
Methia N, Debili N, Titeux M, et al: From the v-mpl oncogene to thrombopoietin. C R Acad Sci III 318:479, 1995.

192.
Vainchenker W, Methia N, Debili N, et al: c-mpl, the thrombopoietin receptor. Thromb Haemost 74:526, 1995.

193.
Wendling F, Vainchenker W: Thrombopoietin and its receptor, the proto-oncogene c-mpl. Curr Opin Hematol 2:331, 1995.

194.
Nomura S, Ogami K, Kawamura K, et al: Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. Exp Hematol 25:565, 1997.

195.
Foster DC, Sprecher CA, Grant FJ, et al: Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. Proc Natl Acad Sci USA 91:13023, 1994.

196.
Gurney AL, Kuang WJ, Xie MH, et al: Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin. Blood 85:981, 1995.

197.
Foster D, Hunt P: The biological significance of truncated and full-length forms of Mpl ligand, in Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology, edited by DJ Kuter, P Hunt, W Sheridan, D Zucker-Franklin, p 203. Humana Press, Ottowa, 1997.

198.
Hokom MM, Lacey D, Kinstler OB, et al: Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. 86:4486, 1995.

199.
Spivack JL, Hogans BB: The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 73:90, 1989.

200.
Foster D, Lok S: Biological roles for the second domain of thrombopoietin. Stem Cells 14(Suppl 1):102, 1996.

201.
Schnittger S, de Sauvage FJ, Le Paslier D, Fonatsch C: Refined chromosomal localization of the human thrombopoietin gene to 3q27-q28 and exclusion as the responsible gene for thrombocytosis in patients with rearrangements of 3q21 and 3q26. Leukemia 10:1891, 1996.

202.
Kaushansky K: Thrombopoietin: the primary regulator of platelet production. Blood 86:419, 1995.

203.
Kuter DJ: Thrombopoietin: biology and clinical applications. Oncologist 1:98, 1996.

204.
Kuter DJ: Thrombopoietin: biology, clinical applications, role in the donor setting. J Clin Apheresis 11:149, 1996.

205.
Kuter DJ, Rosenberg RD: The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 85:2720, 1995.

206.
Fielder PJ, Hass P, Nagel M, et al: Human platelets as a model for the binding and degradation of thrombopoietin. Blood 89:2782, 1997.

207.
Li J, Xia Y, Romo J, Kuter DJ: C-mpl-mediated thrombopoietin internalization in human platelets. Blood 90(Suppl 1):55a, 1997.

208.
Zauli G, Vitale M, Falcieri E, et al: In vitro senescence and apoptotic cell death of human megakaryocytes. Blood 90:2234, 1997.

209.
Bacon CM, Tortolani PJ, Shimosaka A, et al: Thrombopoietin (TPO) induces tyrosine phosphorylation and activation of STAT5 and STAT3. FEBS Lett 370:63, 1995.

210.
Dorsch M, Fan PD, Bogenberger J, Goff SP: TPO and IL-3 induce overlapping but distinct protein tyrosine phosphorylation in a myeloid precursor cell line. Biochem Biophys Res Commun 214:424, 1995.

211.
Drachman JG, Kaushansky K: Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain. Proc Natl Acad Sci USA 94:2350, 1997.

212.
Ezumi Y, Takayama H, Okuma M: Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonist-induced aggregation in platelets in vitro. FEBS Lett 374:48, 1995.

213.
Gurney AL, Wong SC, Henzel WJ, de Sauvage FJ: Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Proc Natl Acad Sci USA 92:5292, 1995.

214.
Miyakawa Y, Oda A, Druker BJ, et al: Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood 87:439, 1996.

215.
Morella KK, Bruno E, Kumaki S, et al: Signal transduction by the receptors for thrombopoietin (c-mpL) and interleukin-3 in hematopoietic and nonhematopoietic cells. Blood 86:557, 1995.

216.
Morita H, Tahara T, Matsumoto A, et al: Functional analysis of the cytoplasmic domain of the human Mpl receptor for tyrosine-phosphorylation of the signaling molecules, proliferation and differentiation. FEBS Lett 395:228, 1996.

217.
Pallard C, Gouilleux F, Benit L, et al: Thrombopoietin activates a STAT5-like factor in hematopoietic cells. Embo J 14:2847, 1995.

218.
Choi ES, Nichol JL, Hokom MM, et al: Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 85:402, 1995.

219.
Kaushansky K, Lin N, Grossmann A, et al: Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol 24:265, 1996.

220.
Basser RL, Rasko JE, Clarke K, et al: Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 348:1279, 1996.

221.
Harker LA, Marzec UM, Hunt P, et al: Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 88:511, 1996.

222.
Harker LA, Hunt P, Marzec UM, et al: Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 87:1833, 1996.

223.
Chen J, Herceg-Harjacek L, Groopman JE, Grabarek J: Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood 86:4054, 1995.

224.
Kubota Y, Arai T, Tanaka T, et al: Thrombopoietin modulates platelet activation in vitro through protein-tyrosine phosphorylation. Stem Cells 14:439, 1996.

225.
Montrucchio G, Brizzi MF, Calosso G, et al: Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood 87:2762, 1996.

226.
Alexander WS, Roberts AW, Nicola NA, et al: Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 87:2162, 1996.

227.
Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW: Thrombocytopenia in c-mpl-deficient mice. Science 265:1445, 1994.

228.
De Sauvage FJ, Carver-Moore K, Luoh SM, et al: Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 183:651, 1996.

229.
Carver-Moore K, Broxmeyer HE, Luoh SM, et al: Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice. Blood 88:803, 1996.

230.
Stoffel R, Wiestner A, Skoda RC: Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 87:567, 1996.

231.
Kuter DJ: The regulation of platelet production, in Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical and Clinical Biology, edited by DJ Kuter, P Hunt, W Sheridan, D Zucker-Franklin, p 377. Humana, Ottowa, 1997.

232.
Bartocci A, Mastrogiannis DS, Migliorati G, et al: Macrophages specifically regulate the concentration of their own growth factor in the circulation. Proc Natl Acad Sci USA 84:6178, 1987.

233.
Layton JE, Hockman H, Sheridan WP, Morstyn G: Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 74:1303, 1989.

234.
Nichol JL: Thrombopoietin levels after chemotherapy and in naturally occurring human diseases. Curr Opin Hematol 5:203, 1998.

235.
Nichol JL, Hokom MM, Hornkohl A, et al: Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 95:2973, 1995.

236.
Penington DG: Studies of platelet production and sequestration in the experimental animal. Proc R Soc Med 61:601, 1968.

237.
Peck-Radosavljevic M, Zacherl J, Meng YG, et al: Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 27:127, 1997.

238.
Karpatkin S: HIV-1-related thrombocytopenia. Hematol Oncol Clin North Am 4:193, 1990.

239.
Harker LA, Carter RA, Marzec UM, et al: Correction of thrombocytopenia and ineffective platelet production in patients infected with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy. Blood 92(Suppl 1):707a, 1998.

240.
Harker LA: Kinetics of thrombopoiesis. J Clin Invest 47:458, 1968.

241.
Harker LA: Regulation of thrombopoiesis. Am J Physiol 218:1376, 1970.

242.
Ballem PJ, Segal GM, Stratton JR, et al: Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. J Clin Invest 80:33, 1987.

243.
Emmons RV, Reid DM, Cohen RL, et al: Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 87:4068, 1996.

244.
Beck JT, Hsu SM, Wijdenes J, et al: Brief report: alleviation of systemic manifestation of Castleman’s disease by monoclonal anti-interleukin-6 antibody. New Engl J Med 330:602, 1994.

245.
Harrison CN, Gale RE, Machin SJ, Linch DC: A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 93:417, 1999.

246.
Li J, Xia Y, Kuter DJ: Analysis of the thrombopoietin receptor (MPL) on platelets from normal and essential thrombocythemic (ET) patients. Blood 88:545a, 1996.

247.
Rosenthal DS, Moloney WS: Refractory dysmyelopoietic anemia and acute leukemia. Blood 63:314, 1984.

248.
Pinto MR, King MA, Goss GD, et al: Acute megakaryoblastic leukaemia with 3q inversion and elevated thrombopoietin (TSF): an autocrine role for TSF? Br J Haematol 61:687, 1985.

249.
Bouscary D, Fontenay-Roupie M, Chretien S, et al: Thrombopoietin is not responsible for the thrombocytosis observed in patients with acute myeloid leukemias and the 3q21q26 syndrome. Br J Haematol 91:425, 1995.

250.
Frey BM, Rafii S, Teterson M, et al: Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol 160:691, 1998.

251.
Kondo T, Okabe M, Sanada M, et al: Familial essential thrombocythemia associated with one-base deletion in the 5′-untranslated region of the thrombopoietin gene. Blood 92:1091, 1998.

252.
Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC: An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 18:49, 1998.

253.
Ghilardi N, Wiestner A, Skoda RC: Thrombopoietin production is inhibited by a translational mechanism. Blood 92:4023, 1998.

254.
Quin S, Fu F, Li W, et al: Primary role of the liver in thrombopoietin production shown by tissue-specific knockout. Blood 92:2189, 1998.

255.
Siemensma NP, Bathal PS, Penington DG: The effect of massive liver resection on platelet kinetics in the rat. J Lab Clin Med 86:817, 1975.

256.
Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al: Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Int Med 126:673, 1997.

257.
Vadhan-Raj S, Verschraegen C, McGarry L, et al: Recombinant human thrombopoietin (rhTPO) attenuates high-dose carboplatin (C)-induced thrombocytopenia in patients with gynecological malignancy. Blood 90:580a, 1997.

258.
Vadhan-Raj S: Recombinant human thrombopoietin: clinical experience and in vivo biology. Semin Hematol 35:261, 1998.

259.
Fanucchi M, Glaspy J, Crawford J, et al: Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 336:404, 1997.

260.
Basser RL, Rasko JE, Clarke K, et al: Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 89:3118, 1997.

261.
Archimbaud E, Ottmann O, Lin J, et al: A randomized, double-blind, placebo-controlled study using PEG-rHuMGDF as an adjunct to chemotherapy for adults with de-novo acute myeloid leukemia (AML): Early results. Blood 99:447a, 1996.

262.
Nash R, Kurzrock R, DiPersio J, et al: Safety and activity of recombinant human thrombopoietin (rhTPO) in patients (pts) with delayed platelet recovery (DPR). Blood 90:262a, 1997.

263.
Bolwell B, Vredenburgh J, Overmoyer B, et al: Safety and biological effect of pegylated recombinant megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients following autologous peripheral blood progenitor cell transplantation (PBPC). Blood 90:171a, 1997.

264.
Glaspy J, Vredenburgh J, Demetri GD, et al: Effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) before high dose chemotherapy (HDC) with peripheral blood progenitor cell (PBPC) support. Blood 90:580a, 1997.

265.
Piacibello W, Sanavio F, Garetto L, et al: Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 89:2644, 1997.

266.
Kuter DJ: The use of PEG-rHuMGDF in platelet apheresis. Stem Cells 16(Suppl 2):231, 1998.

267.
Goodnough LT, DiPersio J, McCullough J, et al: Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increases platelet (PLT) count (CT) and apheresis yields of normal PLT donors: initial results. Transfusion 37:266S, 1997.

268.
Harker LA, Marzec UM, Novembre F, et al: Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor. Blood 91:4427, 1998.

269.
Kaye JA: FDA Licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia, in Thrombopoietin: From Molecule to Medicine, edited by MJ Murphy, DJ Kuter, p 207. AlphaMed Press, Miamisburg, 1998.

270.
Robb L, Li R, Hartley L, et al: Infertility in female mice lacking the receptor for interleukin-11 is due to a defective uterine response to implantation. Nat Med 4:303, 1998.

271.
Nandurkar HH, Robb L, Tarlinton D, et al: Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood 90:2148, 1997.

272.
Giri JG, Smith WG, Kahn LE, et al: Promegapoietin, a chimeric growth factor for megakaryocyte and platelet restoration. Blood 90:580a, 1997.

273.
Cwirla SE, Balasubramanian P, Duffin DJ, et al: Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276:1696, 1997.

274.
Sheridan WP, Kuter DJ: Mechanism of action and clinical trials of Mpl ligand. Curr Opin Hematol 4:312, 1997.

275.
Kuter D: Thrombopoietins and thrombopoiesis: a clinical perspective. Vox Sang 74:75, 1998.

276.
MacVittie TJ, Farese AM, Lind LB, et al: Progenipoietin-G stimulates hematopoietic recovery following myelosuppression. Blood 90:581a, 1997.
Books@Ovid
Copyright © 2001 McGraw-Hill
Ernest Beutler, Marshall A. Lichtman, Barry S. Coller, Thomas J. Kipps, and Uri Seligsohn
Williams Hematology

2 comments on “CHAPTER 110 MEGAKARYOPOIESIS AND THROMBOPOIESIS

  1. […] CYT006-AngQb – Impfstoff gegen Hypertonie » News & Blog – PharmXplorer FocusCHAPTER 110 MEGAKARYOPOIESIS AND THROMBOPOIESIS jQuery.noConflict(); function openKswppwWindow() { if(typeof hide_popup == 'function') { […]

  2. Palasa/Palasha one and the same, it is just how it is pronounced in SOUTH and other parts of India.It basically is Kshara [caustic] prepared from Palasha/Palasa [Butea monosperma, Flame of forest]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: